Physicochemical properties of antibacterial compounds: Implications for drug discovery

Journal of Medicinal Chemistry

Volumn 51, Issue 10, 2008, Pages 2871-2878

  O'Shea, Rosemarie ^a   Moser, Heinz E ^a  

^a Achaogen Inc   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

1 (6 AMINO 3,5 DIFLUORO 2 PYRIDYL) 8 CHLORO 6 FLUORO 1,4 DIHYDRO 7 (3 HYDROXY 1 AZETIDINYL) 4 OXO 3 QUINOLINECARBOXYLIC ACID; 7 [3 (1 AMINOCYCLOPROPYL) 1 PYRROLIDINYL] 1 (2 FLUOROCYCLOPROPYL) 1,4 DIHYDRO 8 METHOXY 4 OXO 3 QUINOLINECARBOXYLIC ACID; AMINOGLYCOSIDE; ANTIINFECTIVE AGENT; AZTREONAM; BETA LACTAM; CARBAPENEM; CEPHEM; CHLORAMPHENICOL; DAPTOMYCIN; DIHYDROFOLATE REDUCTASE INHIBITOR; EP 13420; ERYTHROMYCIN; FOSFOMYCIN; GLYCOPEPTIDE; GRAMICIDIN; LINCOSAMIDE; LORACARBEF; MACROLIDE; MINOCYCLINE; NALIDIXIC ACID; OXAZOLIDINONE DERIVATIVE; PENEM DERIVATIVE; PENICILLIN G; PTK 0796; QUINOLONE; RIFAMYCIN; STREPTOGRAMIN DERIVATIVE; SULFADIMIDINE; SULFANILAMIDE DERIVATIVE; TETRACYCLINE; UNINDEXED DRUG;

ANTIBACTERIAL ACTIVITY; ARTICLE; DRUG BIOAVAILABILITY; DRUG PROTEIN BINDING; DRUG STRUCTURE; GRAM NEGATIVE BACTERIUM; GRAM POSITIVE BACTERIUM; HUMAN; LIPOPHILICITY; PHYSICAL CHEMISTRY;

ANTI-BACTERIAL AGENTS; CHEMISTRY, PHYSICAL; DRUG DESIGN; GRAM-NEGATIVE BACTERIA; GRAM-POSITIVE BACTERIA; HUMANS; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 43949129098     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm700967e     Document Type: Article

References (43)

1. Allsop, A.; Illingworth, R. The impact of genomics and related technologies on the search for new antibiotics. J. Appl. Microbiol. 2002, 92, 7-12.
2. Rice, L. B. Unmet medical needs in antibacterial therapy. Biochem. Pharmacol. 2006, 71, 991-995.
3. Talbot, G. H.; Bradley, J.; Edwards, J. E., Jr.; Gilbert, D.; Scheid, M.; Bartlett, J. G. Bad bugs need drugs: an update on the development pipeline from the Antimicrobial Availability Task Force of the Infectious Diseases Society of America. Clin. Infect. Dis. 2006, 42, 657-668.
4. Overbye, K. M.; Barrett, J. F. Antibiotics: where did we go wrong? Drug Discovery Today 2005, 10, 45-52.
5. Monaghan, R. L.; Barrett, J. F. Antibacterial drug discovery - then, now and the genomics future. Biochem. Pharmacol. 2006, 71, 901-909.
6. Walsh, C. Where will new antibiotics come from? Nat. Rev. Microbiol. 2003, 1, 65-70.
7. Projan, S. J. New (and not so new) antibacterial targets - from where and when will the novel drugs come? Curr. Opin. Pharmacol. 2002, 2, 513-522.
8. Silver, L. L. A retrospective on the failures and successes of antibacterial drug discovery. IDrugs 2005, 8, 651-655.
9. Payne, D. J.; Gwynn, M. N.; Holmes, D. J.; Pompliano, D. L. Drugs for bad bugs: confronting the challenges of antibacterial discovery. Nat. Rev. Drug Discovery 2007, 6, 29-40.
10. Macielag, M. Chemical Properties of Antibacterial Drugs. Presented at the 45th Interscience Conference for Antimicrobial Agents and Chemotherapy (ICAAC), Washington, DC, December 16-19, 2005.
11. Lipinski, C. A.; Lombardo, F.; Dominy, B, W.; Feeney, P. J. Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. Adv. Drug Delivery Rev. 1997, 23, 3-25.
12. Leeson, P. D.; Davis, A. M. Time-related differences in the physical property profiles of oral drugs. J. Med. Chem. 2004, 47, 6338-6348.
13. Garcia-Domenech, R.; de Julian-Ortiz, J. V. Antimicrobial activity characterization in a heterogeneous group of compounds. J. Chem. Inf. Comput. Sci. 1998, 38, 445-449.
14. Mishra, R. K.; Garcia-Domenech, R.; Galvez, J. Getting discriminant functions of antibacterial activity from physicochemical and topological parameters. J. Chem. Inf. Comput. Sci. 2001, 41, 387-393.
15. Tomas-Vert, F.; Perez-Gimenez, F.; Salabert-Salvador, M. T.; Garcia-March, F. J.; Jaen-Oltra, J. Artificial neural network applied to the discrimination of antibacterial activity by topological methods. J. Mol. Struct.: THEOCHEM 2000, 504, 249-259.
16. Cronin, M. T.; Aptula, A. O.; Dearden, J. C.; Duffy, J. C.; Netzeva, T. I.; Patel, H.; Rowe, P. H.; Schultz, T. W.; Worth, A. P.; Voutzoulidis, K.; Schuurmann, G. Structure-based classification of antibacterial activity. J. Chem. Inf. Comput. Sci. 2002, 42, 869-878.
17. Murcia-Soler, M.; Perez-Gimenez, F.; Garcia-March, F. J.; Salabert-Salvador, M. T.; az-Villanueva, W.; Castro-Bleda, M. J.; Villanueva-Pareja, A. Artificial neural networks and linear discriminant analysis: a valuable combination in the selection of new antibacterial compounds. J. Chem. Inf. Comput. Sci. 2004, 44, 1031-1041.
18. Murcia-Soler, M.; Perez-Gimenez, F.; Garcia-March, F. J.; Salabert-Salvador, M. T.; az-Villanueva, W.; Medina-Casamayor, P. Discrimination and selection of new potential antibacterial compounds using simple topological descriptors. J. Mol. Graphics Modell. 2003, 21, 375-390.
19. Molina, E.; Diaz, H. G.; Gonzalez, M. P.; Rodriguez, E.; Uriarte, E. Designing antibacterial compounds through a topological substructural approach. J. Chem. Inf. Comput. Sci. 2004, 44, 515-521.
20. Nikaido, H. Molecular basis of bacterial outer membrane permeability revisited. Microbiol. Mol. Biol. Rev. 2003, 67, 593-656.
21. Hancock, R. E. The bacterial outer membrane as a drug barrier. Trends Microbiol. 1997, 5, 37-42.
22. Li, X. Z.; Nikaido, H. Efflux-mediated drug resistance in bacteria. Drugs 2004, 64, 159-204.
23. Butler, M. S.; Buss, A. D. Natural products - the future scaffolds for novel antibiotics. Biochem. Pharmacol. 2006, 71, 919-929.
24. Silver, L. L. Natural product screening for antibacterial agents. Acta Hortic. 2006, 709, 115-123. (Proceedings of the 1st International Symposium on Natural Preservatives in Food Systems, 2005).
25. Newman, D. J.; Cragg, G. M. Natural products as sources of new drugs over the last 25 years. J. Nat. Prod. 2007, 70, 461-477.
26. Grabowski, K.; Schneider, G. Properties and architecture of drugs and natural products revisited. Curr. Chem. Biol. 2007, 1, 115-127.
27. Magnet, S.; Blanchard, J. S. Molecular insights into aminoglycoside action and resistance, Chem. Rev. 2005, 105, 477-498.
28. Zhanel, G. G.; Dueck, M.; Hoban, D. J.; Vercaigne, L. M.; Embil, J. M.; Gin, A. S.; Karlowsky, J. A. Review of macrolides and ketolides. Drugs 2001, 61, 443-498.
29. Vaara, M. Outer membrane permeability barrier to azithromycin, clarithromycin, and roxithromycin in Gram-negative enteric bacteria. Antimicrob. Agents Chemother. 1993, 37, 354-356.
30. Bosnar, M.; Kelneric, Z.; Munie, V.; Erakovic, V.; Parnham, M. J. Cellular uptake and efflux of azithromycin, erythromycin, clarithromycin, telithromycin, and cethromycin. Antimicrob. Agents Chemother. 2005, 49, 2372-2377.
31. Biegel, A.; Gebauer, S.; Hartrodt, B.; Brandsch, M.; Neubert, K.; Thondorf, I. Three-dimensional quantitative structure-activity relationship analyses of beta-lactam antibiotics and tripeptides as substrates of the mammalian H+/peptide cotransporter PEPT1. J. Med. Chem. 2005, 48, 4410-4419.
32. Hutter, B.; Schaab, C.; Albrecht, S.; Borgmann, M.; Brunner, N. A.; Freiberg, C.; Ziegelbauer, K.; Rock, C. O.; Ivanov, I.; Loferer, H. Prediction of mechanisms of action of antibacterial compounds by gene expression profiling. Antimicrob. Agents Chemother. 2004, 48, 2838-2844.
33. Lipinski, C. A.; Lombardo, F.; Dominy, B. W.; Feeney, P. J. Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. Adv. Drug Delivery Rev. 2001, 46, 3-26.
34. Bergstroem, C. A. S.; Strafford, M.; Lazorova, L.; Avdeef, A.; Luthman, K.; Artursson, P. Absorption classification of oral drugs based on molecular surface properties. J. Med. Chem. 2003, 46, 558-570.
35. Lipinski, C. A. Lead- and drug-like compounds: the rule-of-five revolution. Drug Discovery Today: Technol. 2004, 1, 337-341.
36. Lipinski, C. A. Drug-like properties and the causes of poor solubility and poor permeability. J. Pharmacol. Toxicol. Methods 2001, 44, 235-249.
37. von Nussbaum, F.; Brands, M.; Hinzen, B.; Weigand, S.; Haebich, D. Antibacterial natural products in medicinal chemistry-exodus or revival. Angew. Chem., Int. Ed. 2006, 45, 5072-5129.
38. Clardy, J.; Fischbach, M. A.; Walsh, C. T. New antibiotics from bacterial natural products. Nat. Biotechnol. 2006, 24, 1541-1550.
39. Antibiotics in Laboratory Medicine, 4th ed.; Lorian, V., Ed.; Lippincott Williams & Wilkins: Baltimore, MD, 1996.
40. Ohshita, Y.; Yazaki, A. In Vitro Studies with WQ-3034, a Newly Synthesized Acidic Fluoroquinolone. Presented at the 37th Interscience Conference for Antimicrobial Agents and Chemotherapy (ICAAC), Toronto, Canada, September 28 through October 1, 1997; Poster F-164.
41. Fujikawa, K; Chiba, M; Tanaka, M. In vitro antibacterial activity of DX-619, a novel des-fluoro(6) quinolone. Antimicrob. Agents Chemother. 2005, 49, 3040-3045.
42. Scorneaux, B.; Arya, A.; Polemeropoulos, A.; Lillard, M.; Han, F.; Amsler, K.; Sonderfan, A. J.; Wang, G.; Wang, Y. C.; Peng, Y.; Xu, G.; Kim, H.; Lien, T.; Phan, L.; Or, Y. S. In Vitro and in Vivo Evaluation of EP-13420: A Novel Ketolide Highly Active against Resistant Pathogens and Having Exceptional Pharmacokinetic Properties in the Dog. Presented at the 43rd Interscience Conference for Antimicrobial Agents and Chemotherapy (ICAAC), Chicago, IL, September 14-17, 2003; Poster F-1191.
43. Weir, S.; Macone, A.; Donatelli, J.; Trieber, C.; Taylor, D. E.; Tanaka, S. K.; Levy, S. B. The Activity of PTK 0796 against Tetracycline Resistance. Presented at the 43rd Interscience Conference for Antimicrobial Agents and Chemotherapy (ICAAC), Chicago, IL, September 14-17, 2003; Poster F-752.